Telix Q2 Revenue Hits US$247M; Pipeline Advances

Key Takeaways

• Q2 2026 group revenue reached US$247 million (+7% QoQ, +21% YoY); Precision Medicine contributed US$202 million (+30% YoY).
• Telix expects FY 2026 revenue and other income above US$1 billion, tracking the top of US$950–970 million guidance plus US$40 million Regeneron other income.
• FY 2026 R&D expenditure guidance was raised to US$230–270 million.
• Oncology milestones include ProstACT Global Part 2 FDA alignment, BiPASS 338 patients enrolled, and Pixclara PDUFA 11 September 2026.

Telix Q2 2026 at a glance

Metric	Figure (company disclosure)
Company / tickers	Telix Pharmaceuticals Limited — ASX: TLX, NASDAQ: TLX
Period	Quarter ended 30 June 2026 (Q2 2026)
Group revenue	US$247M (vs US$204M Q2 2025; US$230M Q1 2026)
Precision Medicine	US$202M (+30% YoY, +9% QoQ)
TMS revenue	US$45M (−6% YoY, +2% QoQ)
FY 2026 revenue guide	US$950–970M + US$40M Regeneron other income
FY 2026 R&D guide	US$230–270M (updated)
Pixclara PDUFA	11 September 2026 (FDA-accepted NDA resubmission)

What did the Q2 wire report?

In its 21 July 2026 PR Newswire APAC release, Telix said unaudited Q2 2026 group revenue was US$247 million, up 7% from Q1 2026 and 21% from Q2 2025. Precision Medicine revenue was US$202 million, up 9% sequentially and 30% year-over-year. Telix Manufacturing Solutions (TMS) contributed US$45 million, down 6% year-over-year but up 2% from Q1.

CEO Christian Behrenbruch said US dose volumes rose 7% in the quarter, driven by Gozellix demand and continued strength across the PSMA imaging portfolio. He said the company is tracking the upper end of FY 2026 revenue guidance while increasing R&D investment.

Telix also disclosed a strategic collaboration with Regeneron to jointly develop and commercialize next-generation radiopharmaceutical therapies, initially focused on lung cancer, and said it received a US$40 million non-refundable payment under that collaboration.

How does ASX guidance frame the US$1 billion claim?

Telix’s Q2 wire says FY 2026 revenue and other income should exceed US$1 billion, with product revenue tracking the upper end of US$950 million to US$970 million plus the US$40 million Regeneron other income. That core revenue band matches the FY 2026 guidance Telix set in its 20 February 2026 ASX full-year results announcement, which guided Group revenue of US$950–970 million and then pointed to pipeline R&D of US$200–240 million.

The Q2 update raises R&D expenditure guidance to US$230–270 million, citing commercial performance and the Regeneron payment. Readers should treat Q2 figures as unaudited company market updates, not audited statutory results.

Which oncology therapeutics milestones advanced?

For TLX591-Tx (lutetium-177 rosopatamab tetraxetan), Telix said FDA confirmed Part 1 safety data are sufficient to enable ProstACT Global Phase 3 Part 2 in the United States, and that FDA and Telix aligned on the Part 2 protocol, statistical analysis plan, and safety monitoring. US Part 2 start remains subject to FDA review of an IND amendment. Part 2 continues enrolling where open, including Australia, New Zealand, Canada, Türkiye, the United Kingdom, Singapore, and South Korea, and has regulatory approval to commence in China.

TLX597-Tx’s OPTIMAL-PSMA study completed enrollment of 120 patients, and first patients were dosed in OPTIMAL-e for metastatic hormone-sensitive prostate cancer. For TLX250-Tx, Telix dosed the first patient in LUTEON, a pivotal monotherapy trial in advanced clear-cell renal cell carcinoma with Part 1 expected to enroll up to 40 patients. For TLX101-Tx, the first patient cohort enrolled in Part 1 of IPAX BrIGHT in recurrent glioblastoma, with sites open in Australia, Austria, the Netherlands, and Belgium; IPAX-2 in newly diagnosed glioblastoma completed enrollment with no dose-limiting toxicities observed to date, per the wire.

What is moving in Precision Medicine and Japan?

Telix said BiPASS, a Phase 3 study of Illuccix and Gozellix for initial prostate cancer diagnosis before biopsy, had rapidly enrolled 338 patients and is intended to support submissions in major markets including the US, Europe, and Australia. Japan Phase 3 registrational enrollment for TLX591-Px (Illuccix) is complete; Telix is preparing an NDA and said a Conditional Approval application is under review at Japan’s Pharmaceuticals and Medical Devices Agency (PMDA).

For brain imaging, Telix submitted an IND for a Pixclara Phase 3 indication-expansion study in brain metastases. Separately, FDA accepted the resubmitted NDA for Pixclara (TLX101-Px / 18F-FET) with a PDUFA goal date of 11 September 2026—matching Telix’s earlier 10 April 2026 ASX announcement on FDA NDA acceptance. A European MAA for Pixlumi was validated and accepted for review. Zircaix (TLX250-Px) BLA resubmission work continues, with final CMC documentation nearing completion, Telix said.

What remains unproven for investors?

The Q2 release does not guarantee FY 2026 results above US$1 billion; that is forward-looking company guidance. Pixclara, Zircaix, ProstACT Part 2 US initiation, and Japan Illuccix Conditional Approval remain subject to regulator decisions. Brand names for several pipeline imaging agents remain subject to final approval, as Telix footnotes in related ASX filings.

Related NovaPharma coverage includes TGA Australia drug-approval coverage, Nektar therapeutics pipeline update, and Insilico–Bora alliance analysis.

Frequently Asked Questions

Primary Sources

1. Telix Q2 2026 revenue US$247M market update (PR Newswire APAC, 21 Jul 2026)
2. Telix FY 2025 results / FY 2026 guidance (ASX, 20 Feb 2026)
3. Telix: FDA accepts Pixclara NDA; PDUFA 11 Sep 2026 (ASX, 10 Apr 2026)